325 related articles for article (PubMed ID: 17156337)
1. The allergy-associated chemokine receptors CCR3 and CCR5 can be inactivated by the modified chemokine NNY-CCL11.
Manns J; Rieder S; Escher S; Eilers B; Forssmann WG; Elsner J; Forssmann U
Allergy; 2007 Jan; 62(1):17-24. PubMed ID: 17156337
[TBL] [Abstract][Full Text] [Related]
2. Intravascular inactivation of CCR5 by n-Nonanoyl-CC chemokine ligand 14 and inhibition of allergic airway inflammation.
Gupta S; Fuchs B; Schulz-Maronde S; Heitland A; Escher SE; Mack M; Tillmann HC; Braun A; Forssmann WG; Elsner J; Forssmann U
J Leukoc Biol; 2008 Mar; 83(3):765-73. PubMed ID: 18063698
[TBL] [Abstract][Full Text] [Related]
3. n-Nonanoyl-CCL14 (NNY-CCL14), a novel inhibitor of allergic airway inflammation is a partial agonist of human CCR2.
Gupta S; Erdmann G; Schulz-Maronde S; Escher SE; Richter R; Forssmann WG; Elsner J; Forssmann U
Allergy; 2008 Oct; 63(10):1317-23. PubMed ID: 18782110
[TBL] [Abstract][Full Text] [Related]
4. CCR1- and CCR5-mediated inactivation of leukocytes by a nonglycosaminoglycan (non-GAG)-binding variant of n-nonanoyl-CCL14 (NNY-CCL14).
Gupta S; Rieder S; Richter R; Schulz-Maronde S; Manns J; Escher SE; Heitland A; Mack M; Forssmann WG; Elsner J; Forssmann U
J Leukoc Biol; 2010 Aug; 88(2):383-92. PubMed ID: 20483925
[TBL] [Abstract][Full Text] [Related]
5. n-Nonanoyl-CC chemokine ligand 14, a potent CC chemokine ligand 14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation.
Forssmann U; Hartung I; Bälder R; Fuchs B; Escher SE; Spodsberg N; Dulkys Y; Walden M; Heitland A; Braun A; Forssmann WG; Elsner J
J Immunol; 2004 Sep; 173(5):3456-66. PubMed ID: 15322211
[TBL] [Abstract][Full Text] [Related]
6. A novel, selective, and orally available antagonist for CC chemokine receptor 3.
Morokata T; Suzuki K; Masunaga Y; Taguchi K; Morihira K; Sato I; Fujii M; Takizawa S; Torii Y; Yamamoto N; Kaneko M; Yamada T; Takahashi K; Shimizu Y
J Pharmacol Exp Ther; 2006 Apr; 317(1):244-50. PubMed ID: 16339911
[TBL] [Abstract][Full Text] [Related]
7. The carboxyl terminus of the chemokine receptor CCR3 contains distinct domains which regulate chemotactic signaling and receptor down-regulation in a ligand-dependent manner.
Sabroe I; Jorritsma A; Stubbs VE; Xanthou G; Jopling LA; Ponath PD; Williams TJ; Murphy PM; Pease JE
Eur J Immunol; 2005 Apr; 35(4):1301-10. PubMed ID: 15739168
[TBL] [Abstract][Full Text] [Related]
8. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3.
Struyf S; Proost P; Schols D; De Clercq E; Opdenakker G; Lenaerts JP; Detheux M; Parmentier M; De Meester I; Scharpé S; Van Damme J
J Immunol; 1999 Apr; 162(8):4903-9. PubMed ID: 10202035
[TBL] [Abstract][Full Text] [Related]
9. Alanine scanning mutagenesis of the chemokine receptor CCR3 reveals distinct extracellular residues involved in recognition of the eotaxin family of chemokines.
Duchesnes CE; Murphy PM; Williams TJ; Pease JE
Mol Immunol; 2006 Mar; 43(8):1221-31. PubMed ID: 16102831
[TBL] [Abstract][Full Text] [Related]
10. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
Xanthou G; Duchesnes CE; Williams TJ; Pease JE
Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of novel antagonists of the CCR3 receptor.
Warrior U; McKeegan EM; Rottinghaus SM; Garcia L; Traphagen L; Grayson G; Komater V; McNally T; Helfrich R; Harris RR; Bell RL; Burns DJ
J Biomol Screen; 2003 Jun; 8(3):324-31. PubMed ID: 12857386
[TBL] [Abstract][Full Text] [Related]
12. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.
Heath H; Qin S; Rao P; Wu L; LaRosa G; Kassam N; Ponath PD; Mackay CR
J Clin Invest; 1997 Jan; 99(2):178-84. PubMed ID: 9005985
[TBL] [Abstract][Full Text] [Related]
13. Significance of N-terminal proteolysis of CCL14a to activity on the chemokine receptors CCR1 and CCR5 and the human cytomegalovirus-encoded chemokine receptor US28.
Richter R; Casarosa P; Ständker L; Münch J; Springael JY; Nijmeijer S; Forssmann WG; Vischer HF; Vakili J; Detheux M; Parmentier M; Leurs R; Smit MJ
J Immunol; 2009 Jul; 183(2):1229-37. PubMed ID: 19553544
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptor antagonists: a novel therapeutic approach in allergic diseases.
Elsner J; Escher SE; Forssmann U
Allergy; 2004 Dec; 59(12):1243-58. PubMed ID: 15507091
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of respiratory syncytial virus infection with the CC chemokine RANTES (CCL5).
Elliott MB; Tebbey PW; Pryharski KS; Scheuer CA; Laughlin TS; Hancock GE
J Med Virol; 2004 Jun; 73(2):300-8. PubMed ID: 15122808
[TBL] [Abstract][Full Text] [Related]
16. I-TAC/CXCL11 is a natural antagonist for CCR5.
Petkovic V; Moghini C; Paoletti S; Uguccioni M; Gerber B
J Leukoc Biol; 2004 Sep; 76(3):701-8. PubMed ID: 15178708
[TBL] [Abstract][Full Text] [Related]
17. CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.
He J; Chen Y; Farzan M; Choe H; Ohagen A; Gartner S; Busciglio J; Yang X; Hofmann W; Newman W; Mackay CR; Sodroski J; Gabuzda D
Nature; 1997 Feb; 385(6617):645-9. PubMed ID: 9024664
[TBL] [Abstract][Full Text] [Related]
18. N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.
Batt DG; Houghton GC; Roderick J; Santella JB; Wacker DA; Welch PK; Orlovsky YI; Wadman EA; Trzaskos JM; Davies P; Decicco CP; Carter PH
Bioorg Med Chem Lett; 2005 Feb; 15(3):787-91. PubMed ID: 15664858
[TBL] [Abstract][Full Text] [Related]
19. A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor.
Suzuki K; Morokata T; Morihira K; Sato I; Takizawa S; Kaneko M; Takahashi K; Shimizu Y
Eur J Pharmacol; 2007 Jun; 563(1-3):224-32. PubMed ID: 17336292
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma.
Jöhrer K; Zelle-Rieser C; Perathoner A; Moser P; Hager M; Ramoner R; Gander H; Höltl L; Bartsch G; Greil R; Thurnher M
Clin Cancer Res; 2005 Apr; 11(7):2459-65. PubMed ID: 15814620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
